Double-blind randomized trial of progesterone to prevent preterm birth in second-trimester bleeding

Raed Salim, Marwan Hakim, Noah Zafran, Zohar Nachum, Shabtai Romano, Gali Garmi, Raed Salim, Marwan Hakim, Noah Zafran, Zohar Nachum, Shabtai Romano, Gali Garmi

Abstract

Introduction: Second-trimester vaginal bleeding increases the risk of spontaneous preterm birth. We aimed to examine the efficacy of vaginal progesterone to reduce preterm birth rate in women with second-trimester vaginal bleeding.

Material and methods: Two-center, double-blind, placebo-controlled trial involving pregnant women with second-trimester vaginal bleeding. Women with documented uterine bleeding were randomly assigned in a 1:1 ratio to receive 200 mg of micronized vaginal progesterone or placebo once daily at 16-26 weeks until 36 weeks of gestation. Women who had prior preterm birth or short cervix diagnosed before recruitment were not eligible. The primary outcome was spontaneous delivery <37 weeks.

Clinical trial registration: clinicaltrials.gov Identifier: NCT01269450.

Results: Between March 2011 and January 2017, 128 women gave consent and were randomized; 16 withdrew consent and 3 had a second-trimester termination of pregnancy. The final analysis included 109 women: 60 in the progesterone group and 49 in the placebo group. Demographic and obstetric characteristics did not differ between the groups. Primary outcome occurred in 19 (31.7%) and 12 (24.5%) in the progesterone and placebo groups, respectively (odds ratio [OR] 1.32; 95% confidence interval [CI] 0.55-3.16; P = 0.53). The proportion of births <34 weeks was similar between the groups (OR 1.19; 95% CI 0.47-3.02; P = 0.72), as were the survival curves from randomization to delivery (hazard ratio, 1.24; 95% CI, 0.60-2.56; P = 0.57). There were no significant differences in neonatal morbidities between the groups. The study was ended prematurely because of slow recruitment.

Conclusions: Antepartum vaginal progesterone does not seem to reduce the incidence of preterm birth in women with second-trimester bleeding.

Keywords: preterm birth; second-trimester bleeding; vaginal progesterone.

© 2019 Nordic Federation of Societies of Obstetrics and Gynecology.

References

REFERENCES

    1. Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol. 2008;112:963-965.
    1. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385.
    1. Romero R, Nicolaides KH, Conde-Agudelo A, et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol. 2016;48:308-317.
    1. Saccone G, Schoen C, Franasiak JM, Scott RT Jr, Berghella V. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107:430-438.
    1. Norman JE, Marlow N, Messow CM, et al.; OPPTIMUM Study Group. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387:2106-2116.
    1. Axelsen SM, Henriksen TB, Hedegaard M, Secher NJ. Characteristics of vaginal bleeding during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1995;63:131-1314.
    1. Sipila P, Hartikainen-Sorri A. Perinatal outcome of pregnancies complicated by vaginal bleeding. Br J Obstet Gynecol. 1992;99:959-963.
    1. Parant O, Clouet-Delannoy M, Connan L, Duclusaud A, Chale J, Fournié A. Metrorrhagia during the second trimester of pregnancy: obstetrical and perinatal outcome. A retrospective study including 85 cases. J Gynecol Obstet Biol Reprod (Paris). 2000;29:66-72.
    1. Koifman A, Levy A, Zaulan Y, et al. The clinical significance of bleeding during the second trimester of pregnancy. Arch Gynecol Obstet. 2008;278:47-51.
    1. Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Am J Obstet Gynecol. 2001;185:1059-1063.
    1. Rosen T, Kuczynski E, O'Neill LM, Funai EF, Lockwood CJ. Plasma levels of thrombin-antithrombin complexes predict preterm premature rupture of the fetal membranes. J Matern Fetal Med. 2001;10:297-300.
    1. Cakmak H, Schatz F, Huang ST, et al. Progestin suppresses thrombin- and interleukin-1β-induced interleukin-11 production in term decidual cells: implications for preterm delivery. J Clin Endocrinol Metab. 2005;90:5279-5286.
    1. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
    1. Tooher RL, Middleton PF, Crowther CA. A thematic analysis of factors influencing recruitment to maternal and perinatal trials. BMC Pregnancy Childbirth. 2008;8:36.
    1. Watson J, Torgerson D. Increasing recruitment to randomised trials: a review of randomised controlled trials. BMC Med Res Methodol. 2006;6:34.
    1. Committee on Practice Bulletins-Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964-973.
    1. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol. 2017;216:B11-B13.
    1. Signore CC, Sood AK, Richards DS. Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome. Am J Obstet Gynecol. 1998;178:336-340.
    1. Hammouda A. Bleeding in the first two trimesters of pregnancy. Review of 1000 cases. Int Surg. 1966;45:447-449.
    1. Scott J. Vaginal bleeding in the midtrimester of pregnancy. Am J Obstet Gynecol. 1972;113:329-334.
    1. Chan CC, To WW. Antepartum hemorrhage of unknown origin-what is its clinical significance? Acta Obstet Gynecol Scand. 1999;78:186-190.
    1. Gabbe SG, Niebyl JR, Simpson JL, eds. Antepartum and Postpartum Hemorrhage. 7th ed. St. Louis: CV Mosby; 1983:403.
    1. Lockwood C, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med. 1999;27:5-20.
    1. Elovitz MA, Baron J, Phillippe M. The role of thrombin in preterm parturition. Transactions of the Twenty-First Annual Meeting of the Society for Maternal-Fetal Medicine. Am J Obstet Gynecol. 2001;185:1059-1063.
    1. Buhimschi CS, Schatz F, Krikun G, Buhimschi IA, Lockwood CJ. Novel insights into molecular mechanisms of abruption-induced preterm birth. Expert Rev Mol Med. 2010;12:e35.
    1. Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev. 2009;23:167.
    1. Lockwood CJ, Kayisli UA, Stocco C, et al. Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells. Am J Pathol. 2012;181:2138.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren